16,559 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Kiley Juergens Wealth Management LLC

Kiley Juergens Wealth Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,559 shares of the company’s stock, valued at approximately $2,126,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Westside Investment Management Inc. grew its position in Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after buying an additional 649 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Novo Nordisk A/S by 38.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after purchasing an additional 26,067 shares during the last quarter. Advisor Resource Council acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $997,000. Procyon Advisors LLC grew its position in shares of Novo Nordisk A/S by 47.7% in the fourth quarter. Procyon Advisors LLC now owns 55,026 shares of the company’s stock valued at $5,692,000 after purchasing an additional 17,783 shares during the last quarter. Finally, McKinley Carter Wealth Services Inc. grew its position in shares of Novo Nordisk A/S by 37.0% in the fourth quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock valued at $6,244,000 after purchasing an additional 16,293 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.3 %

Shares of NVO traded down $1.88 on Wednesday, hitting $141.10. 677,641 shares of the stock traded hands, compared to its average volume of 4,427,745. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $633.19 billion, a P/E ratio of 49.31, a P/E/G ratio of 1.42 and a beta of 0.41. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $148.15. The stock’s 50 day moving average is $135.40 and its two-hundred day moving average is $124.04.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Argus increased their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.